Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.

Autor: Sun H; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China., Li L; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China., Bu F; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China., Xin X; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China., Yan J; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China. jingchao.yan@fdeent.org., Huang T; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China. taominhuang@126.com.
Jazyk: angličtina
Zdroj: Eye (London, England) [Eye (Lond)] 2024 Dec; Vol. 38 (18), pp. 3473-3480. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1038/s41433-024-03327-3
Abstrakt: Objectives: To compare the 2-year efficacy and safety of various anti-vascular endothelial growth factor (VEGF) regimens for neovascular age-related macular degeneration (nAMD).
Methods: A comprehensive search was performed on multiple electronic databases up to April 2023 and updated in June 2024, to identify relevant randomized controlled trials (RCTs). Key outcomes included the proportion of patients achieving a vision gain of ≥15 letters and maintaining stable vision (loss of <15 letters) in best-corrected visual acuity (BCVA), changes in mean BCVA from baseline, serious ocular adverse events (SAEs), adverse events leading to treatment discontinuation and any cause of death at 2 years.
Results: Nineteen trials with 12,654 patients and 25 treatment regimens were analyzed in the study. All anti-VEGF regimens showed superior efficacy compared to sham therapy. Specifically, faricimab 6 mg (4+up to Q16W) and ranibizumab 0.5 mg (2-week T&E) displayed top-level effect in vision gain. Bevacizumab 1.25 mg (2-week T&E) and aflibercept 2 mg (2-week T&E) demonstrated the most stable vision outcomes. Bevacizumab 1.25 mg (2-week T&E) and ranibizumab 0.5 mg (2-week T&E) exhibited the most pronounced mean BCVA improvement. Compared to sham therapy, the risk of SAEs was significantly higher for brolucizumab 6 mg (3 + Q12W/ Q8W) (RR = 6.04, 95% CI: 1.30-28.02) and PDS 100 mg/ml (Q24W) (RR = 10.95, 95% CI: 2.14-56.02), but not for other anti-VEGF regimens.
Conclusions: Ranibizumab 0.5 mg (2-week T&E) emerges as a potentially optimal regimen for nAMD over a 2-year period. Future studies need to consider the impact of baseline characteristics on treatment outcomes.
Competing Interests: Competing interests: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz: